Copley Acquisition and Ignite Proteomics Enter Definitive Business Combination Agreement
Copley Acquisition Corp and Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"), a company in pathway-level protein analytics to guide precision oncology, announced that they have entered into a definitive business combination agreement. Upon the closing of the Combination, Copley and Ignite Proteomics will become wholly owned subsidiaries of a newly formed public holding company, which is intended to be named Ignite Proteomics Holdings, and which will be listed on the New York Stock Exchange. The proposed Combination is expected to close in the second half of 2026, subject to customary closing conditions.
